Facebook Twitter

SMITHKLINE BEECHAM TO PROMOTE THERATECH

SHARE SMITHKLINE BEECHAM TO PROMOTE THERATECH

TheraTech Inc., 417 Wakara Way, has signed an agreement with SmithKline Beecham, giving the latter the exclusive North American marketing and distribution rights of TheraTech's testosterone transdermal delivery system used in the treatment of testosterone deficiencies in males.

Dinesh C. Patel, TheraTech president, said the agreement grants his company future co-promotion rights in the United States. Under the agreement, TheraTech receives $3 million.